Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  2017-09-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD011572.pub2PMID 28886205PMCID PMC6483671
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tripeptide K(D)PT Is Well Tolerated in Mild-to-moderate Ulcerative Colitis: Results from a Randomized Multicenter Study

  2017cited by this paper
• Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.

  2016cited by this paper
• Safety and efficacy of a novel IV targeted pegylated liposomal prednisolone product (Nanocort): results from a phase 2a study in patients with active ulcerative colitis

  2016cited by this paper
• Randomised clinical trial: a phase 1, dose‐ranging study of the anti‐matrix metalloproteinase‐9 monoclonal antibody GS‐5745 versus placebo for ulcerative colitis

  2016cited by this paper
• Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study.

  2016cited by this paper
• AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial.

  2016cited by this paper
• Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis

  2016cited by this paper
• Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.

  2016cited by this paper
• 767 Efficacy and Safety of Oral Tofacitinib As Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis: Results From Two Phase 3 Randomized Controlled Trials

  2016cited by this paper
• Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

  2016cited by this paper
• Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis.

  2015cited by this paper
• Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis

  2015cited by this paper
• Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study

  2015cited by this paper
• Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis

  2015cited by this paper
• Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis

  2015cited by this paper
• 745 Methotrexate for Corticosteroid-Dependent Ulcerative Colitis: Results of a Placebo Randomized Controlled Trial

  2015cited by this paper
• 370 AJM300, an oral a4 integrin antagonist, for active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled phase 2a study

  2014cited by this paper
• 370 AJM300, an Oral α4 Integrin Antagonist, for Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2A Study

  2014cited by this paper
• P394 Pooled clinical trial analysis of MMX mesalazine safety: Focus on 4.8 g/d dose long-term exposure

  2014cited by this paper
• O-001 Budesonide MMX® 9 mg for Inducing Remission in Patients With Mild-to-Moderate Ulcerative Colitis Not Adequately Controlled With Oral 5-ASAs

  2014cited by this paper
• DOP058 Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies

  2014cited by this paper
• OP011 Tralokinumab (CAT-354), an interleukin 13 antibody, in moderate to severe ulcerative colitis: A phase 2 randomized placebo-controlled study

  2014cited by this paper
• P552 Association between Week 8 Mayo subscores and hospitalisation rates in adalimumab-treated patients with ulcerative colitis from ULTRA 1 and ULTRA 2

  2014cited by this paper
• Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.

  2014cited by this paper
• Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study

  2014cited by this paper
• OP009 Long-term safety and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: Results from the PURSUIT-SC Maintenance study extension

  2014cited by this paper
• First Multicenter Study of Modified Release Phosphatidylcholine “LT-02” in Ulcerative Colitis: A Randomized, Placebo-Controlled Trial in Mesalazine-Refractory Courses

  2014cited by this paper
• Mo1223 Health-Related Quality of Life in Patients With Ulcerative Colitis After Treatment With Vedolizumab: Results From the Gemini 1 Study

  2014cited by this paper
• P501 Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders

  2014cited by this paper
• Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.

  2014cited by this paper
• Etrolizumab in moderate-to-severe ulcerative colitis.

  2014cited by this paper
• Effects of Increased Vedolizumab Dosing Frequency on Disease Activity in Ulcerative Colitis and Crohn’s Disease: 1618

  2014cited by this paper
• DOP076 Improvements in health-related quality of life in patients with ulcerative colitis treated with vedolizumab

  2014cited by this paper
• Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.

  2014cited by this paper
• 865 Phase IIB, Randomized, Placebo-Controlled Evaluation of the Efficacy and Safety of Induction Therapy With Eldelumab (Anti-IP-10 Antibody; BMS-936557) in Patients With Active Ulcerative Colitis

  2014cited by this paper
• Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation – a placebo‐controlled study

  2013cited by this paper
• P391 Rates of “patient-defined” remission with adalimumab in patients with ulcerative colitis: subanalysis of ULTRA 1 and ULTRA 2

  2013cited by this paper
• Erythrocytes-mediated Delivery of Dexamethasone 21-phosphate in Steroid-dependent Ulcerative Colitis: A Randomized, Double-blind Sham-controlled Study

  2013cited by this paper
• Sa1219 Efficacy of Budesonide MMx® in Reduction of Symptoms in Patients With Mild-to-Moderately Active Ulcerative Colitis: A Pooled Analysis of the CORE I and CORE II Studies

  2013cited by this paper
• P-148 Budesonide MMX Versus Placebo in Patients with Active, Mild-to-Moderate Ulcerative Colitis who Were 5-ASA Naïve or Previously Treated with 5-ASA

  2013cited by this paper
• Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

  2013cited by this paper
• Sa1220 Budesonide MMx® 9 mg Induces Remission in Mild-to-Moderately Active UC Patients Regardless of Prior History of 5-ASA Therapy

  2013cited by this paper
• P568 Sustained efficacy in patients with ulcerative colitis treated with adalimumab: results from ULTRA 2

  2013cited by this paper
• Comparative Efficacy of Adalimumab, Golimumab, and Infliximab in the Treatment of Patients with Ulcerative Colitis: An Induction Analysis: 1707

  2013cited by this paper
• 52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants

  2013cited by this paper
• Asia–Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma

  2013cited by this paper
• Trial designs and exploration of the placebo response.

  2013cited by this paper
• P-149 Efficacy and Safety of Budesonide Foam for Inducing Remission in Mildly to Moderately Active Ulcerative Proctitis or Ulcerative Proctosigmoiditis

  2013cited by this paper
• P-140 Pharmacokinetic/Pharmacodynamic Relationship and Immunogenicity of Vedolizumab in Adults with Inflammatory Bowel Disease: Additional Results from GEMINI 1 and 2

  2013cited by this paper
• Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study

  2013cited by this paper
• P513 Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo-controlled, double-blind, multi-centre trial

  2013cited by this paper
• Sa1208 Sustained Efficacy in Patients With Ulcerative Colitis Treated With Adalimumab: Results From ULTRA 2

  2013cited by this paper
• P323 Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo-controlled, double-blind, multicenter trial

  2013cited by this paper
• The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis.

  2013cited by this paper
• P-141 Association Between Week 8 Mayo Subscores and Hospitalisation Rates in Adalimumab-treated Patients with Ulcerative Colitis from ULTRA1 and ULTRA2

  2013cited by this paper
• Sa1195 Exposure-Efficacy Relationship (ER) for Adalimumab During Induction Phase of Treatment of Adult Patients With Moderate to Severe Ulcerative Colitis

  2013cited by this paper
• The placebo response in medicine: minimize, maximize or personalize?

  2013cited by this paper
• Vedolizumab as induction and maintenance therapy for ulcerative colitis.

  2013cited by this paper
• Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study

  2013cited by this paper
• Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis.

  2012cited by this paper
• Efficacy of Vedolizumab in Ulcerative Colitis by Prior Treatment Failure in GEMINI I, a Randomized, Placebo‐Controlled, Double‐Blind, Multicenter Trial: O‐1b

  2012cited by this paper
• Mesalazine granules 1.5 g once‐daily maintain remission in patients with ulcerative colitis who switch from other 5‐ASA formulations: a pooled analysis from two randomised controlled trials

  2012cited by this paper
• PMO-235 A randomised placebo-controlled double-blind study of Octasa® 4.8 g/day (800 mg tablets 5-ASA) for the induction of endoscopic remission in patients with active ulcerative colitis

  2012cited by this paper
• P353 MMX® a mesalazine and long-term safety: A pooled analysis

  2012cited by this paper
• Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial: 1522

  2012cited by this paper
• Double‐blind, placebo‐controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid‐refractory ulcerative colitis

  2012cited by this paper
• Sustained Therapeutic Benefit of Vedolizumab Throughout 1 Year in Ulcerative Colitis in GEMINI I, a Randomized, Placebo‐Controlled, Double‐Blind, Multicenter Trial: P‐27

  2012cited by this paper
• Abatacept for Crohn's disease and ulcerative colitis.

  2012cited by this paper
• 943b Induction Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial

  2012cited by this paper
• Long‐term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT‐1 and ‐2 Extension Studies

  2012cited by this paper
• P162 Induction of clinical and endoscopic remission with budesonide MMX in mild to moderately active ulcerative colitis: Pooled data from two phase 3 studies

  2012cited by this paper
• Efficacy of Vedolizumab in Ulcerative Colitis by Prior Treatment Failure in GEM‐INI I, a Randomized, Placebo‐Controlled, Double‐Blind, Multicenter Trial: P‐29

  2012cited by this paper
• Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

  2012cited by this paper
• Adalimumab Induction Dose Reduces the Risk of Hospitalizations and Colectomies in Patients with Ulcerative Colitis During the First 8 Weeks of Therapy: 1601

  2012cited by this paper
• Reduced Steroid Usage in Ulcerative Colitis Patients With Week 8 Response to Adalimumab: Subanalysis of ULTRA 2: P-21

  2012cited by this paper
• Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

  2012cited by this paper
• A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

  2012cited by this paper
• Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.

  2012cited by this paper
• Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis

  2012cited by this paper
• Induction of remission with oral budesonide MMX (R) (9 mg) tablets in oatients with mild to moderate, active Ulcerative Colitis: A multicenter, open-label efficacy and safety study

  2011cited by this paper
• Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

  2011cited by this paper
• Induction and Maintenance of Clinical Remission by Adalimumab in Patients With Moderate-to-Severe Ulcerative Colitis

  2011cited by this paper
• Induction of Clinical and Endoscopic Remission of Mild to Moderately Active Ulcerative Colitis With Budesonide MMX (R) 9 mg: Analysis of Pooled Data from Two Phase 3 Studies

  2011cited by this paper
• Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis – additional results from two controlled studies

  2011cited by this paper
• Pooled Safety Analysis of Long-term MMX®,a Mesalamine Administration: P-43.

  2011cited by this paper
• Randomised clinical trial: early assessment after 2 weeks of high‐dose mesalazine for moderately active ulcerative colitis – new light on a familiar question

  2011cited by this paper
• The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study

  2011cited by this paper
• Random effects meta‐analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data

  2010cited by this paper
• Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis.

  2010cited by this paper
• Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis

  2010cited by this paper
• Randomized, Double-blind, Placebo-Controlled Trial of Andrographis Paniculata Extract (HMPL-004) in Patients with Moderately Active Crohnʼs Disease: 1180

  2010cited by this paper
• Clinical trial: once‐daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6‐month placebo‐controlled trial

  2010cited by this paper
• Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis

  2010cited by this paper
• Effect of extended MMX mesalamine therapy for acute, mild‐to‐moderate Ulcerative Colitis

  2009cited by this paper
• Safety and Efficacy of a New 3.3 g b.i.d. Tablet Formulation in Patients With Mild-to-Moderately-Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

  2009cited by this paper
• Induction of mucosal healing in mild-to-moderate ulcerative colitis in patients treated with MMX mesalamine: established versus newly diagnosed disease: P-0096.

  2009cited by this paper
• MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis.

  2009cited by this paper
• Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials

  2009cited by this paper
• 387 A Placebo-Controlled Trial of Visilizumab in Patients with Intravenous (IV) Steroid Refractory Ulcerative Colitis (UC)

  2009cited by this paper
• Meta-analysis of the placebo response in antidepressant trials.

  2009cited by this paper

• A scoping review of placebo and nocebo responses and effects: insights for clinical trials and practice

  2025influential citation
• Placebo rates in randomized clinical trials of ulcerative colitis: an individual patient data meta-analysis

  2025cites this paper
• ScreeningLessons from Prediction and Prevention of Type 1 Diabetes.

  2025cites this paper
• The Use and Role of Mesalamine in the Treatment of Ulcerative Colitis: A Literature Review

  2025cites this paper
• What the Patient Thinks and What the Patient Does: Placebo, Nocebo, and Therapy Adherence in Ulcerative Colitis

  2025influential citation
• Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis in induction and maintenance: systematic literature review and Bayesian network meta-analysis

  2025cites this paper
• Food-Based Interventions as Therapy for Inflammatory Bowel Disease: Important Steps in Diet Trial Design and Reporting of Outcomes.

  2024cites this paper
• Efficacy and Safety of Anthocyanin-Rich Extract in Patients with Ulcerative Colitis: A Randomized Controlled Trial

  2024cites this paper
• Partial Enteral Nutrition in the Management of Crohn’s Disease: A Systematic Review and Meta-Analysis

  2024cites this paper
• Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysis

  2024cites this paper
• Harms with placebo in trials of biological therapies and small molecules as induction therapy in inflammatory bowel disease: a systematic review and meta-analysis.

  2024cites this paper
• Consistent efficacy outcomes between phase 2 and phase 3 trials in Crohn’s disease or ulcerative colitis in adults: a meta-analysis

  2024cites this paper
• Endoscopic and Histological Placebo Rates in Crohn's Disease Clinical Trials: A Systematic Review and Meta-analysis.

  2023cites this paper
• A review on the use of prebiotics in ulcerative colitis.

  2023cites this paper
• Niclosamide Enema for Active Distal Ulcerative Colitis: A Phase 1, Open-Label Study.

  2023cites this paper
• Risk-Benefit of IBD Drugs: A Physicians and Patients Survey

  2023cites this paper
• Histological Remission Placebo Rates in Ulcerative Colitis Trials: A Systematic Review and Meta-analysis.

  2023cites this paper
• The underappreciated placebo effects and responses in randomized controlled trials on neck pain: a systematic review with meta-analysis.

  2022cites this paper
• Systematic review and meta-analysis of the placebo effect in panic disorder: Implications for research and clinical practice

  2022cites this paper
• A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation

  2022cites this paper
• Predictors of Placebo Induction Response and Remission in Ulcerative Colitis.

  2022cites this paper
• Response and Adverse Event Rates with Placebo in Gastroparesis: A Systematic Review and Meta-analysis.

  2022cites this paper
• Annexin A1 based inflammation resolving mediators and nanomedicines for inflammatory bowel disease therapy.

  2022cites this paper
• Identifying anti-TNF response biomarkers in ulcerative colitis using a diffusion-based signalling model

  2021cites this paper
• Current recommendations on the role of diet in the aetiology and management of IBD

  2021cites this paper
• Breaking the therapeutic ceiling in drug development in ulcerative colitis.

  2021cites this paper
• The Relieving Effects of a Polyherb-Based Dietary Supplement ColonVita on Gastrointestinal Quality of Life Index (GIQLI) in Older Adults with Chronic Gastrointestinal Symptoms Are Influenced by Age and Cardiovascular Disease: A 12-Week Randomized Placebo-Controlled Trial

  2021cites this paper
• Meta-Analysis: Placebo Response and Its Determinants in Functional Dyspepsia

  2021cites this paper
• PLACEBO USE IN THE CONTEXT OF INFLAMMATORY BOWEL DISEASE CLINICAL TRIALS.

  2020cites this paper
• Increasing number of authors in Cochrane reviews

  2020cites this paper
• Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid?

  2020cites this paper
• Interrogating the Gut-Brain Axis in the Context of Inflammatory Bowel Disease: A Translational Approach

  2020cites this paper
• The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

  2020cites this paper
• Probiotics for maintenance of remission in ulcerative colitis.

  2020cites this paper
• Low FODMAP Diet for Functional Gastrointestinal Symptoms in Quiescent Inflammatory Bowel Disease: A Systematic Review of Randomized Controlled Trials

  2020cites this paper
• Clinical, endoscopic and histological outcomes in induction of moderate-to-severe ulcerative colitis: a systematic review with meta-analysis.

  2020cites this paper
• Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis

  2020cites this paper
• Systematic review with meta‐analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies

  2019cites this paper
• Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation

  2019cites this paper
• Multidonor FMT capsules improve symptoms and decrease fecal calprotectin in ulcerative colitis patients while treated – an open-label pilot study

  2019cites this paper
• Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study

  2019cites this paper
• Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis.

  2019cites this paper
• Systematic review with meta‐analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis

  2018cites this paper
• Placebo Rates in Randomized Controlled Trials of Pouchitis Therapy

  2018cites this paper
• Evolution of Clinical Trials in Inflammatory Bowel Diseases

  2018cites this paper
• The rise of biosimilars: Balancing innovation with affordable biologic alternatives

  year unknowncites this paper
• AJG-21-0593 2184..2196

  year unknowncites this paper